Repeated antipsychotic treatment progressively potentiates inhibition on phencyclidine-induced hyperlocomotion, but attenuates inhibition on amphetamine-induced hyperlocomotion: relevance to animal models of antipsychotic drugs - PubMed (original) (raw)
. 2009 Jan 14;602(2-3):334-42.
doi: 10.1016/j.ejphar.2008.11.036. Epub 2008 Nov 27.
Affiliations
- PMID: 19059234
- DOI: 10.1016/j.ejphar.2008.11.036
Repeated antipsychotic treatment progressively potentiates inhibition on phencyclidine-induced hyperlocomotion, but attenuates inhibition on amphetamine-induced hyperlocomotion: relevance to animal models of antipsychotic drugs
Tao Sun et al. Eur J Pharmacol. 2009.
Abstract
Clinical observations indicate that antipsychotic action starts early and increases in magnitude with repeated treatment. Animal models that faithfully capture this time course of action are few. Inhibition of hyperlocomotion induced by amphetamine or phencyclidine has been widely used as a screening tool for the antipsychotic activity of a drug. We thus investigated whether repeated antipsychotic treatment could produce an early-onset and progressively increased antagonistic effect on amphetamine or phencyclidine-induced hyperlocomotion as a way of assessing the validity of such models in capturing time course of antipsychotic action. On each of the five consecutive test days, different groups of rats (n=6-7/group) received an initial injection of either haloperidol (0.01-0.10 mg/kg, sc), clozapine (5-20.0 mg/kg, sc), olanzapine (1.0 mg/kg, sc), chlordiazepoxide (10.0 mg/kg, ip) or vehicle (sterile water, sc) 30 min prior to a second injection of either amphetamine (1.5 mg/kg, sc) or phencyclidine (3.2 mg/kg, sc). Motor activity was subsequently monitored for 60 min after amphetamine or phencyclidine treatment. Repeated treatment of haloperidol, clozapine, or olanzapine progressively potentiated inhibition on repeated phencyclidine-induced hyperlocomotion and prolonged this action over the five consecutive days. In contrast, antipsychotic inhibition on repeated amphetamine-induced hyperlocomotion was gradually attenuated and shortened. Repeated treatment of chlordiazepoxide, a benzodiazepine anxiolytic, retained its inhibition on amphetamine-induced hyperlocomotion, but had no effect on phencyclidine-induced one. These results suggest that repeated phencyclidine-induced hyperlocomotion model based on repeated antipsychotic treatment regimen is capable of capturing the progressive increase pattern of antipsychotic treatment seen in the clinic and differentiating antipsychotics from anxiolytics; thus it may serve as a better model for the investigation of the neurobiological mechanisms of action of antipsychotic drugs and delineating the pathophysiology of schizophrenia.
Similar articles
- Neural basis of the potentiated inhibition of repeated haloperidol and clozapine treatment on the phencyclidine-induced hyperlocomotion.
Zhao C, Sun T, Li M. Zhao C, et al. Prog Neuropsychopharmacol Biol Psychiatry. 2012 Aug 7;38(2):175-82. doi: 10.1016/j.pnpbp.2012.03.007. Epub 2012 Mar 26. Prog Neuropsychopharmacol Biol Psychiatry. 2012. PMID: 22476004 Free PMC article. - Repeated asenapine treatment produces a sensitization effect in two preclinical tests of antipsychotic activity.
Qin R, Chen Y, Li M. Qin R, et al. Neuropharmacology. 2013 Dec;75:356-64. doi: 10.1016/j.neuropharm.2013.05.031. Epub 2013 Aug 14. Neuropharmacology. 2013. PMID: 23954676 Free PMC article. - Effect of environmental cues on the behavioral efficacy of haloperidol, olanzapine, and clozapine in rats.
Sun T, Liu X, Li M. Sun T, et al. Behav Pharmacol. 2014 Aug;25(4):277-86. doi: 10.1097/FBP.0000000000000047. Behav Pharmacol. 2014. PMID: 24949569 Free PMC article. - Influence of long-lasting administration of neuroleptics on cortical NMDA receptors and phencyclidine-induced deficit in the sensorimotor gating in rats.
Ossowska K, Pietraszek M, Wardas J, Nowak G, Wolfarth S. Ossowska K, et al. Pol J Pharmacol. 1999 Jan-Feb;51(1):49-53. Pol J Pharmacol. 1999. PMID: 10389144 Review. - Animal behavior models of the mechanisms underlying antipsychotic atypicality.
Geyer MA, Ellenbroek B. Geyer MA, et al. Prog Neuropsychopharmacol Biol Psychiatry. 2003 Oct;27(7):1071-9. doi: 10.1016/j.pnpbp.2003.09.003. Prog Neuropsychopharmacol Biol Psychiatry. 2003. PMID: 14642967 Review.
Cited by
- Zelquistinel Is an Orally Bioavailable Novel NMDA Receptor Allosteric Modulator That Exhibits Rapid and Sustained Antidepressant-Like Effects.
Burgdorf JS, Zhang XL, Stanton PK, Moskal JR, Donello JE. Burgdorf JS, et al. Int J Neuropsychopharmacol. 2022 Dec 12;25(12):979-991. doi: 10.1093/ijnp/pyac043. Int J Neuropsychopharmacol. 2022. PMID: 35882204 Free PMC article. - Apocynin-Tandospirone Derivatives Suppress Methamphetamine-Induced Hyperlocomotion in Rats with Neonatal Exposure to Dizocilpine.
Uehara T, Kurachi M, Kondo T, Abe H, Itoh H, Sumiyoshi T, Suzuki M. Uehara T, et al. J Pers Med. 2022 Feb 27;12(3):366. doi: 10.3390/jpm12030366. J Pers Med. 2022. PMID: 35330366 Free PMC article. - Behavioral Alterations and Decreased Number of Parvalbumin-Positive Interneurons in Wistar Rats after Maternal Immune Activation by Lipopolysaccharide: Sex Matters.
Vojtechova I, Maleninska K, Kutna V, Klovrza O, Tuckova K, Petrasek T, Stuchlik A. Vojtechova I, et al. Int J Mol Sci. 2021 Mar 23;22(6):3274. doi: 10.3390/ijms22063274. Int J Mol Sci. 2021. PMID: 33806936 Free PMC article. - Antipsychotic-induced sensitization and tolerance: Behavioral characteristics, developmental impacts, and neurobiological mechanisms.
Li M. Li M. J Psychopharmacol. 2016 Aug;30(8):749-70. doi: 10.1177/0269881116654697. Epub 2016 Jul 1. J Psychopharmacol. 2016. PMID: 27371498 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources